http://www.opednews.com/articles/The-Me-Too-Drug-Rip-Off-by-Dr-Stuart-Jeanne-B-110514-761.htmlIn addition to the billions of health care dollars drug companies waste on disease mongering -- convincing the public that everyday human problems are actually illnesses requiring treatment -- billions more are wasted on developing and marketing hundreds of "me-too" drugs. By definition, a "me-too" or "copycat" drug is a very slight variation of an existing drug that is already on the market. The main downside of me-too drugs is that they are a primary factor in skyrocketing health care costs, which in turn, are the main reason hundreds of thousands of Americans can't afford to see a doctor when they are ill. Other drawbacks of Big Pharma's fixation with copycat drugs include the neglect of hundreds of untreatable fatal and disabling illnesses and hundreds of cases of premature death and/or permanent disability related to inadequate safety profiling. Nearly all the major drug recalls in the last few years have involved copycat drugs that were assumed safe because they were chemically similar to medications already on the market.
An Issue First Raised by Ralph Nader
I first learned about me-too drugs when Ralph Nader raised the issue in his 2000 presidential campaign. Dr Marcia Angell, Harvard Senior Lecturer in Social Medicine covers the subject extensively in The Truth About the Drug Companies: How They Deceive Us and What To Do About It (2004) and in "Excess in the pharmaceutical industry" in the Canadian Medical Association Journal
http://www.cmaj.ca/cgi/content/full/171/12/1451According to Angell, it's quite common for a drug company to manufacture their own copycat drugs when their patent is about to expire on an older drug (which means most doctors and patients will opt for the cheaper generics that become available). She gives the example of AstraZeneca reformulating the ulcer drug Priloxec to bring out Nexium, a nearly identical replacement and then increasing the price of the Prilosec to get people to switch.
More at the link --